06 June 2022
- Results will provide a first-of-its kind dataset – adding to the substantial amounts of scientific evidence generated about Vuse, the number one global vaping brand i
- Unique cross-sectional approach will provide a snapshot of the differences in indicators of potential harm between Vuse consumers compared to smokers
- Demonstrates BAT’s focus on science and innovation to deliver A Better Tomorrow™ and reduce the health impact of its business
BAT has conducted a first-of-its-kind study of Vuse designed to assess and provide insights into the real-world health impact of vaping. The study compares biomarker measures from Vuse ii consumers who have been using the product for over six months with the results from smokers, former smokers and never smokers. Protocol details explaining the innovative design of the latest study were published in the Journal of Health and Environmental Research iii .
The cross-sectional study design uses a single set of data readings to measure exposure to certain toxicants and indicators of potential harm related to several smoking-related diseases in people who have been exclusively using Vuse.
The biomarkers selected are important indicators that can be used to demonstrate:
- Biomarkers of Exposure: A person’s exposure to certain toxicants or chemicals iv
- Biomarkers of Potential Harm: Indicators of potential harm related to several smoking-related diseases, such as respiratory or cardiovascular disease iii
It is hoped that the results, which are currently being analysed and will be published later this year, will provide further supportive evidence that using Vuse can reduce relative risk for certain diseases among adult consumers compared to smoking. It is expected that once available, the results will add to the growing body of evidence on Vuse’s potential as a Reduced-Risk Product*.
Watch the animation below to learn more about the study
Watch an interview with Dr Sharon Goodall, BAT’s Head of Regulatory Science, who talks about the significance of the study and why it is so important
Dr Sharon Goodall, BAT’s Group Head of Regulatory Sciences, said: “This innovative study demonstrates our commitment to researching the reduced-risk potential of our New Category products. What makes it particularly relevant and exciting is that the results generated will be from people who have been using Vuse as they normally would for more than six months prior to testing. The results will provide important new insights and show us the differences between Vuse users, smokers and former smokers across a range of important biomarkers thought to be predictive of disease development. We look forward to sharing the data once available.”
About the study
Participants in the study were Vuse
ii
users who had been exclusively using the product for over six months. Smoking or vapour usage patterns and overall consumption were not controlled in those entering the study, as the aim was to assess the impact when people using the products did so in their ‘normal’ way rather than in a controlled way. Four different groups were enrolled.
These comprised:
- Current smokers who had been smoking for at least one year prior to screening
- Vuse vapers (ePod and ePen) for at least six months
- Former smokers who had quit for at least six months
- Never smokers were included to act as a control group
Participants were based in the UK, aged between 19-55 years old, and in good general health.
Unlike longitudinal studies where participants attend multiple clinic visits over an extended period of time, participants in this study made a single clinic visit where samples of blood, urine and other measurements were collected. These samples were then tested for “biomarkers of exposure” (to selected cigarette smoke toxicants) and “biomarkers of potential harm”. Differences between the groups were assessed, rather than changes from baseline.
In addition, to ensure compliance, the Vuse and former smoker groups were tested for the biomarker, CEVal, which indicates if they have recently smoked cigarettes.
Results from the completed study will be published in due course.
* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk-free and are addictive.
† Our products as sold in the U.S., including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to Food and Drug Administration (FDA) regulation and no reduced-risk claims will be made as to these products without FDA clearance.
i Based on Vype/Vuse estimated value share from RRP in measured retail for vapour (i.e. total vapour category value in retail sales) in the USA, Canada, France, UK, Germany.These 5 markets cover an estimated 77% of global vapour closed system NTO, calculated in June - July 2021.
ii Vuse ePod and/or ePen3. Both are closed vapour systems
iii Nathan Gale, Linsey Ellen Haswell, Michael McEwan, David Azzopardi, Jesse Thissen, George Hardie. Biomarkers of Exposure and Potential Harm in Exclusive Users of Electronic Cigarettes and Current, Former and Never-Smokers: A Cross-Sectional Study Protocol.
iv Journal of Health and Environmental Research. Vol. 8, No. 2, 2022, pp. 116-127. doi: 10.11648/j.jher.20220802.17
v WHO Study Group on Tobacco Regulation. Report on the Scientific Basis of Tobacco Product Regulation: Fifth Report of a WHO Study Group. 2015.
Enquiries
Press Office
+44 (0) 20 7845 2888 (24 hours)
Forward-looking statements
This release contains certain forward-looking statements, including "forward-looking" statements made within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "believe," "anticipate," "could," "may," "would," "should," "intend," "plan," "potential," "predict," "will," "expect," "estimate," "project," "positioned," "strategy," "outlook", "target" and similar expressions. These include statements regarding our customer target ambition, New Categories revenue targets and our ESG targets.
All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors. It is believed that the expectations reflected in this release are reasonable but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated. A review of the reasons why actual results and developments may differ materially from the expectations disclosed or implied within forward-looking statements can be found by referring to the information contained under the headings “Cautionary Statement” and "Group Principal Risks " in the 2021 Annual Report and Form 20-F of British American Tobacco p.l.c. (BAT).
Additional information concerning these and other factors can be found in BAT's filings with the U.S. Securities and Exchange Commission ("SEC"), including the Annual Report on Form 20-F and Current Reports on Form 6-K, which may be obtained free of charge at the SEC's website, http://www.sec.gov and BAT’s Annual Reports, which may be obtained free of charge from the BAT website www.bat.com.
Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser. The forward-looking statements reflect knowledge and information available at the date of preparation of this release and BAT undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.